- Published on
Infectious Disease and Microbiology – Pneumonia
Pneumonia is defined as inflammation of the pulmonary parenchyma caused by an infectious agent. Pneumonia can be categorized according to the clinical setting in which it occurs. These categories include community-acquired pneumonia (CAP), which may be typical or atypical; pneumonia occurring in nursing-home residents; nosocomial pneumonia, including hospital-acquired and ventilator-associated pneumonia; pneumonia in immunocompromised hosts; and aspiration pneumonia.
Pneumonia is a major cause of morbidity and mortality worldwide. Approximately 4 million patients develop pneumonia annually in the United States. Community-acquired pneumonia affects about 12 per 1,000 inhabitants each year, with the highest incidence occurring at the extremes of age. Nosocomial pneumonia develops in approximately 0.5–1.5% of hospitalized patients and is particularly common among mechanically ventilated patients, especially those ventilated for prolonged periods. CAP is more common in children and adults older than 60 years.
Several important risk factors predispose individuals to pneumonia. These include alcoholism, aspiration, endotracheal intubation, immunosuppression, age greater than 65 years, hospitalization or nursing-home residence, particularly ICU stay, and underlying pulmonary diseases such as COPD and cystic fibrosis. Preventive measures include influenza and pneumococcal vaccination and minimizing the duration of endotracheal intubation whenever possible.
The pathophysiology of pneumonia involves activation of the host inflammatory response. Inflammatory mediators and chemokines released by macrophages and recruited neutrophils increase alveolar-capillary permeability, leading to alveolar filling with fluid and inflammatory cells. This results in infiltrates, rales, hemoptysis, hypoxemia, decreased lung compliance, and dyspnea. Increased respiratory drive, airway secretions, and infection-related bronchospasm further contribute to respiratory symptoms.
The etiology of pneumonia varies depending on the clinical setting. In community-acquired pneumonia, Streptococcus pneumoniae remains the most common pathogen. Other important organisms include Mycoplasma pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Staphylococcus aureus, particularly following influenza infection. Community-acquired MRSA strains may cause necrotizing or cavitary pneumonia. Viral pathogens such as hantaviruses, metapneumoviruses, and coronaviruses including SARS are also implicated. Polymicrobial infections are common, and Coxiella burnetii is an important atypical pathogen.
Nosocomial pneumonia is usually caused by gram-negative bacilli such as multidrug-resistant Pseudomonas, Klebsiella, Acinetobacter, and Xanthomonas species. MRSA is also common. Anaerobic bacteria and Legionella species may occasionally be involved, particularly in outbreaks related to contaminated water supplies.
In immunocompromised hosts, the responsible pathogens depend on the nature of the immune defect. Patients with humoral immune deficiencies are susceptible to S. pneumoniae, H. influenzae, S. aureus, and Neisseria species. Granulocyte dysfunction predisposes to gram-negative bacilli and Aspergillus infections. Cellular immune deficiencies increase susceptibility to fungal infections such as Pneumocystis jiroveci, Candida, and Cryptococcus; parasitic infections such as Toxoplasma and Strongyloides; mycobacterial infections; and viral infections including CMV and herpesviruses.
Patients with community-acquired pneumonia often report a recent upper respiratory tract infection. Symptoms commonly include fever, cough, sputum production, pleuritic chest pain, dyspnea, chills, sweats, fatigue, headache, myalgias, and arthralgias. Elderly patients may present atypically with confusion or altered mental status. Nosocomial pneumonia should be suspected in hospitalized patients after more than 48 hours of admission.
Physical examination commonly reveals tachypnea and tachycardia. Tactile fremitus may be increased or decreased. Percussion may demonstrate dullness due to consolidation or pleural fluid. Crackles, bronchial breath sounds, and pleural friction rubs may be present. Severe disease may manifest with hypotension or evidence of organ failure.
Initial laboratory evaluation includes complete blood count, pulse oximetry or arterial blood gas measurements, inflammatory markers such as C-reactive protein, and microbiologic cultures obtained from uncontaminated respiratory specimens. Chest radiography is the primary imaging study. If the initial chest radiograph is negative despite strong clinical suspicion, repeat imaging or chest CT may be necessary. Pneumatoceles suggest S. aureus infection, while upper-lobe cavitary lesions raise suspicion for tuberculosis. CT scanning may help identify post-obstructive pneumonia due to tumors or foreign bodies.
Additional diagnostic procedures may be required in severely ill or diagnostically challenging cases. These include bronchoscopy with bronchoalveolar lavage, transbronchial biopsy, lung biopsy, PCR testing, urinary antigen testing for S. pneumoniae and Legionella, and quantitative cultures. Concurrent endocarditis or meningitis should be excluded when clinically suspected.
The differential diagnosis includes infectious conditions such as bronchitis, empyema, lung abscess, and acute exacerbations of chronic bronchitis, as well as noninfectious conditions such as congestive heart failure, pulmonary embolism, lung cancer, and lymphoma.
Empiric antimicrobial therapy depends on the severity and setting of pneumonia. Outpatients with community-acquired pneumonia who are previously healthy and have not received recent antibiotics may be treated with azithromycin, clarithromycin, or doxycycline. Patients with comorbidities or recent antibiotic exposure should receive either a respiratory fluoroquinolone or a beta-lactam combined with a macrolide. Hospitalized non-ICU patients are generally treated with a respiratory fluoroquinolone or a beta-lactam plus macrolide. ICU patients require broader therapy with a beta-lactam plus azithromycin or a fluoroquinolone. If Pseudomonas is suspected, antipseudomonal agents are required, and linezolid should be added when CA-MRSA is suspected.
Treatment duration for CAP is generally at least 5 days, although many patients require 7–10 days of therapy. Longer treatment courses are necessary for infections due to Legionella, Coxiella burnetii, or S. aureus. Nosocomial pneumonia without MDR risk factors may be treated with ceftriaxone, respiratory fluoroquinolones, ampicillin-sulbactam, or ertapenem. Patients at risk for multidrug-resistant organisms require broad-spectrum antipseudomonal beta-lactams combined with aminoglycosides or fluoroquinolones and MRSA coverage with vancomycin or linezolid.
Supportive management includes adequate hydration, oxygen therapy, and assisted ventilation when necessary. Early administration of empiric antibiotics is critical and should ideally occur within 4 hours of hospital arrival. Severity assessment tools such as CURB-65 and the Pneumonia Severity Index help determine the need for hospitalization.
Patients should be monitored closely for oxygen saturation and clinical response. Discharge is appropriate once the patient is clinically improved, afebrile for at least 72 hours, hemodynamically stable, and able to tolerate oral antibiotics.
Radiographic abnormalities may take 4–12 weeks to resolve. Persistent or recurrent pneumonia should prompt evaluation for underlying malignancy or structural lung disease. Prognosis is generally excellent in outpatients with CAP, with mortality rates below 1%. Mortality rises to approximately 10% among hospitalized patients and is significantly higher in ventilator-associated pneumonia.
Complications include treatment failure due to resistant organisms, inadequate therapy, or noninfectious mimics; metastatic infection; complicated pleural effusions; and lung abscess formation.
Pneumonia is defined as inflammation of the pulmonary parenchyma caused by an infectious agent. Pneumonia can be categorized according to the clinical setting in which it occurs. These categories include community-acquired pneumonia (CAP), which may be typical or atypical; pneumonia occurring in nursing-home residents; nosocomial pneumonia, including hospital-acquired and ventilator-associated pneumonia; pneumonia in immunocompromised hosts; and aspiration pneumonia.
Pneumonia is a major cause of morbidity and mortality worldwide. Approximately 4 million patients develop pneumonia annually in the United States. Community-acquired pneumonia affects about 12 per 1,000 inhabitants each year, with the highest incidence occurring at the extremes of age. Nosocomial pneumonia develops in approximately 0.5–1.5% of hospitalized patients and is particularly common among mechanically ventilated patients, especially those ventilated for prolonged periods. CAP is more common in children and adults older than 60 years.
Several important risk factors predispose individuals to pneumonia. These include alcoholism, aspiration, endotracheal intubation, immunosuppression, age greater than 65 years, hospitalization or nursing-home residence, particularly ICU stay, and underlying pulmonary diseases such as COPD and cystic fibrosis. Preventive measures include influenza and pneumococcal vaccination and minimizing the duration of endotracheal intubation whenever possible.
The pathophysiology of pneumonia involves activation of the host inflammatory response. Inflammatory mediators and chemokines released by macrophages and recruited neutrophils increase alveolar-capillary permeability, leading to alveolar filling with fluid and inflammatory cells. This results in infiltrates, rales, hemoptysis, hypoxemia, decreased lung compliance, and dyspnea. Increased respiratory drive, airway secretions, and infection-related bronchospasm further contribute to respiratory symptoms.
The etiology of pneumonia varies depending on the clinical setting. In community-acquired pneumonia, Streptococcus pneumoniae remains the most common pathogen. Other important organisms include Mycoplasma pneumoniae, Haemophilus influenzae, Chlamydia pneumoniae, and Staphylococcus aureus, particularly following influenza infection. Community-acquired MRSA strains may cause necrotizing or cavitary pneumonia. Viral pathogens such as hantaviruses, metapneumoviruses, and coronaviruses including SARS are also implicated. Polymicrobial infections are common, and Coxiella burnetii is an important atypical pathogen.
Nosocomial pneumonia is usually caused by gram-negative bacilli such as multidrug-resistant Pseudomonas, Klebsiella, Acinetobacter, and Xanthomonas species. MRSA is also common. Anaerobic bacteria and Legionella species may occasionally be involved, particularly in outbreaks related to contaminated water supplies.
In immunocompromised hosts, the responsible pathogens depend on the nature of the immune defect. Patients with humoral immune deficiencies are susceptible to S. pneumoniae, H. influenzae, S. aureus, and Neisseria species. Granulocyte dysfunction predisposes to gram-negative bacilli and Aspergillus infections. Cellular immune deficiencies increase susceptibility to fungal infections such as Pneumocystis jiroveci, Candida, and Cryptococcus; parasitic infections such as Toxoplasma and Strongyloides; mycobacterial infections; and viral infections including CMV and herpesviruses.
Patients with community-acquired pneumonia often report a recent upper respiratory tract infection. Symptoms commonly include fever, cough, sputum production, pleuritic chest pain, dyspnea, chills, sweats, fatigue, headache, myalgias, and arthralgias. Elderly patients may present atypically with confusion or altered mental status. Nosocomial pneumonia should be suspected in hospitalized patients after more than 48 hours of admission.
Physical examination commonly reveals tachypnea and tachycardia. Tactile fremitus may be increased or decreased. Percussion may demonstrate dullness due to consolidation or pleural fluid. Crackles, bronchial breath sounds, and pleural friction rubs may be present. Severe disease may manifest with hypotension or evidence of organ failure.
Initial laboratory evaluation includes complete blood count, pulse oximetry or arterial blood gas measurements, inflammatory markers such as C-reactive protein, and microbiologic cultures obtained from uncontaminated respiratory specimens. Chest radiography is the primary imaging study. If the initial chest radiograph is negative despite strong clinical suspicion, repeat imaging or chest CT may be necessary. Pneumatoceles suggest S. aureus infection, while upper-lobe cavitary lesions raise suspicion for tuberculosis. CT scanning may help identify post-obstructive pneumonia due to tumors or foreign bodies.
Additional diagnostic procedures may be required in severely ill or diagnostically challenging cases. These include bronchoscopy with bronchoalveolar lavage, transbronchial biopsy, lung biopsy, PCR testing, urinary antigen testing for S. pneumoniae and Legionella, and quantitative cultures. Concurrent endocarditis or meningitis should be excluded when clinically suspected.
The differential diagnosis includes infectious conditions such as bronchitis, empyema, lung abscess, and acute exacerbations of chronic bronchitis, as well as noninfectious conditions such as congestive heart failure, pulmonary embolism, lung cancer, and lymphoma.
Empiric antimicrobial therapy depends on the severity and setting of pneumonia. Outpatients with community-acquired pneumonia who are previously healthy and have not received recent antibiotics may be treated with azithromycin, clarithromycin, or doxycycline. Patients with comorbidities or recent antibiotic exposure should receive either a respiratory fluoroquinolone or a beta-lactam combined with a macrolide. Hospitalized non-ICU patients are generally treated with a respiratory fluoroquinolone or a beta-lactam plus macrolide. ICU patients require broader therapy with a beta-lactam plus azithromycin or a fluoroquinolone. If Pseudomonas is suspected, antipseudomonal agents are required, and linezolid should be added when CA-MRSA is suspected.
Treatment duration for CAP is generally at least 5 days, although many patients require 7–10 days of therapy. Longer treatment courses are necessary for infections due to Legionella, Coxiella burnetii, or S. aureus. Nosocomial pneumonia without MDR risk factors may be treated with ceftriaxone, respiratory fluoroquinolones, ampicillin-sulbactam, or ertapenem. Patients at risk for multidrug-resistant organisms require broad-spectrum antipseudomonal beta-lactams combined with aminoglycosides or fluoroquinolones and MRSA coverage with vancomycin or linezolid.
Supportive management includes adequate hydration, oxygen therapy, and assisted ventilation when necessary. Early administration of empiric antibiotics is critical and should ideally occur within 4 hours of hospital arrival. Severity assessment tools such as CURB-65 and the Pneumonia Severity Index help determine the need for hospitalization.
Patients should be monitored closely for oxygen saturation and clinical response. Discharge is appropriate once the patient is clinically improved, afebrile for at least 72 hours, hemodynamically stable, and able to tolerate oral antibiotics.
Radiographic abnormalities may take 4–12 weeks to resolve. Persistent or recurrent pneumonia should prompt evaluation for underlying malignancy or structural lung disease. Prognosis is generally excellent in outpatients with CAP, with mortality rates below 1%. Mortality rises to approximately 10% among hospitalized patients and is significantly higher in ventilator-associated pneumonia.
Complications include treatment failure due to resistant organisms, inadequate therapy, or noninfectious mimics; metastatic infection; complicated pleural effusions; and lung abscess formation.
- Published on
Infectious Disease and Microbiology -Pneumocystis jiroveci (Carinii) Infection
Pneumocystis jiroveci is an opportunistic fungal pathogen whose natural habitat is the lung. It is an important cause of pneumonia in immunocompromised patients, especially individuals with HIV/AIDS. The disease is commonly referred to as Pneumocystis pneumonia (PCP). Although formerly known as Pneumocystis carinii, the organism infecting humans is now correctly termed Pneumocystis jiroveci. Despite advances in prophylaxis and antiretroviral therapy, PCP remains one of the most common opportunistic infections in HIV-infected patients.
The incidence of PCP has decreased substantially because of routine prophylaxis and improved HIV management. However, it still occurs frequently among patients with advanced immunosuppression. PCP has also been reported in patients receiving immunomodulatory therapies such as infliximab and etanercept. Extrapulmonary disease is uncommon, occurring in fewer than 3% of cases. Internationally, the reported incidence is considered low, although this is likely due to underdiagnosis. PCP is particularly important in HIV-infected infants, among whom it is responsible for a large proportion of pneumonia cases.
Major risk factors include HIV/AIDS with CD4 counts below 200/mm³, malignancy, long-term corticosteroid or immunosuppressive therapy, primary immunodeficiency syndromes, tobacco use, and severe malnutrition. Patients with organ transplants, hematologic malignancies, and severe combined immunodeficiency are also at increased risk. Because of these risks, prophylaxis is recommended for high-risk HIV-infected individuals and certain other immunocompromised populations.
Primary prophylaxis is indicated in HIV-infected patients with CD4 counts below 200/mm³ or in those with oropharyngeal candidiasis regardless of CD4 count. The preferred prophylactic regimen is one double-strength tablet of trimethoprim-sulfamethoxazole daily. Alternative regimens include reduced-dose TMP-SMX, dapsone-based regimens, nebulized pentamidine, or pyrimethamine combinations. Secondary prophylaxis is recommended for all patients recovering from PCP until immune reconstitution occurs.
Infection with P. jiroveci usually occurs early in childhood, and many healthy individuals harbor the organism in their lungs without disease. In immunocompromised hosts, defective cellular immunity—especially impaired CD4 T-cell function—prevents effective clearance of the organism. Activated macrophages become unable to eliminate the fungus, resulting in increased alveolar-capillary permeability and impaired gas exchange. This process produces hypoxemia, respiratory alkalosis, and diffuse interstitial pneumonia.
Patients usually present with nonspecific symptoms such as progressive exertional dyspnea, fever, dry cough, chest discomfort, chills, and weight loss. In HIV-infected individuals, the illness often develops gradually over days to weeks, whereas in non-HIV immunocompromised patients the disease may progress rapidly and severely. Hemoptysis is uncommon but may occur.
On physical examination, patients commonly have tachypnea, fever, and tachycardia. Pulmonary examination may be surprisingly normal in up to half of patients despite significant hypoxemia. Children with severe disease may exhibit cyanosis, nasal flaring, and intercostal retractions. Rare extrapulmonary manifestations can involve the central nervous system, thyroid, gastrointestinal tract, lymph nodes, eyes, and bone marrow.
Laboratory findings are nonspecific. Elevated lactate dehydrogenase (LDH) levels are common but not diagnostic. Serum β-D-glucan levels are frequently elevated. Arterial blood gas analysis typically demonstrates hypoxemia, respiratory alkalosis, and an increased alveolar–arterial oxygen gradient. Disease severity is often classified according to the degree of alveolar–arterial gradient elevation.
Chest radiography classically demonstrates bilateral diffuse perihilar infiltrates, although early disease may show a normal chest x-ray. Chest CT scanning is more sensitive and commonly reveals diffuse bilateral ground-glass opacities. Patients receiving aerosolized pentamidine prophylaxis may show upper-lobe infiltrates and are at increased risk for pneumothorax.
Definitive diagnosis requires identification of the organism in respiratory specimens. Fiberoptic bronchoscopy with bronchoalveolar lavage remains the diagnostic standard. Induced sputum may be used but has variable sensitivity. Histopathologic stains such as methenamine silver, toluidine blue, Giemsa, and immunofluorescent stains are used to identify cysts and trophozoites. More invasive procedures such as transbronchial biopsy or open-lung biopsy are reserved for difficult cases.
The differential diagnosis includes other causes of diffuse pneumonia and respiratory failure, including tuberculosis, cytomegalovirus pneumonia, viral pneumonias, Legionella infection, fungal pneumonias, pulmonary embolism, ARDS, congestive heart failure, and pulmonary involvement by Kaposi sarcoma or lymphoma.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the treatment of choice for PCP. The recommended dose is 15–20 mg/kg/day of the trimethoprim component, administered orally or intravenously in divided doses. Treatment duration is 21 days in HIV-infected patients and 14 days in non-HIV patients. Clinical improvement usually occurs within several days, although clinicians should wait at least 4–8 days before concluding treatment failure.
Adjunctive corticosteroids significantly improve survival in patients with moderate to severe disease, particularly in HIV-associated PCP. Steroids are indicated in patients with a PaO₂ below 70 mm Hg or an alveolar–arterial gradient greater than or equal to 35 mm Hg. Prednisone is typically administered in tapering doses over 21 days and should be started within 72 hours of initiating antimicrobial therapy.
Alternative therapies are used when TMP-SMX cannot be tolerated or when treatment failure occurs. Intravenous pentamidine is an effective alternative but may cause significant toxicities including hypotension, arrhythmias, pancreatitis, dysglycemia, renal dysfunction, electrolyte abnormalities, and neutropenia. Other options include clindamycin plus primaquine, atovaquone, or trimethoprim plus dapsone. Primaquine should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency.
Patients require close monitoring for clinical response, oxygenation status, and medication-related adverse effects. Complications include progressive respiratory failure, pneumothorax, concurrent pulmonary infections, and death. Mortality rates are approximately 10–20% among HIV-infected patients but may reach 30–50% in non-HIV immunocompromised individuals, largely due to delayed diagnosis and treatment. Early recognition and prompt therapy remain essential for improving outcomes.
Pneumocystis jiroveci is an opportunistic fungal pathogen whose natural habitat is the lung. It is an important cause of pneumonia in immunocompromised patients, especially individuals with HIV/AIDS. The disease is commonly referred to as Pneumocystis pneumonia (PCP). Although formerly known as Pneumocystis carinii, the organism infecting humans is now correctly termed Pneumocystis jiroveci. Despite advances in prophylaxis and antiretroviral therapy, PCP remains one of the most common opportunistic infections in HIV-infected patients.
The incidence of PCP has decreased substantially because of routine prophylaxis and improved HIV management. However, it still occurs frequently among patients with advanced immunosuppression. PCP has also been reported in patients receiving immunomodulatory therapies such as infliximab and etanercept. Extrapulmonary disease is uncommon, occurring in fewer than 3% of cases. Internationally, the reported incidence is considered low, although this is likely due to underdiagnosis. PCP is particularly important in HIV-infected infants, among whom it is responsible for a large proportion of pneumonia cases.
Major risk factors include HIV/AIDS with CD4 counts below 200/mm³, malignancy, long-term corticosteroid or immunosuppressive therapy, primary immunodeficiency syndromes, tobacco use, and severe malnutrition. Patients with organ transplants, hematologic malignancies, and severe combined immunodeficiency are also at increased risk. Because of these risks, prophylaxis is recommended for high-risk HIV-infected individuals and certain other immunocompromised populations.
Primary prophylaxis is indicated in HIV-infected patients with CD4 counts below 200/mm³ or in those with oropharyngeal candidiasis regardless of CD4 count. The preferred prophylactic regimen is one double-strength tablet of trimethoprim-sulfamethoxazole daily. Alternative regimens include reduced-dose TMP-SMX, dapsone-based regimens, nebulized pentamidine, or pyrimethamine combinations. Secondary prophylaxis is recommended for all patients recovering from PCP until immune reconstitution occurs.
Infection with P. jiroveci usually occurs early in childhood, and many healthy individuals harbor the organism in their lungs without disease. In immunocompromised hosts, defective cellular immunity—especially impaired CD4 T-cell function—prevents effective clearance of the organism. Activated macrophages become unable to eliminate the fungus, resulting in increased alveolar-capillary permeability and impaired gas exchange. This process produces hypoxemia, respiratory alkalosis, and diffuse interstitial pneumonia.
Patients usually present with nonspecific symptoms such as progressive exertional dyspnea, fever, dry cough, chest discomfort, chills, and weight loss. In HIV-infected individuals, the illness often develops gradually over days to weeks, whereas in non-HIV immunocompromised patients the disease may progress rapidly and severely. Hemoptysis is uncommon but may occur.
On physical examination, patients commonly have tachypnea, fever, and tachycardia. Pulmonary examination may be surprisingly normal in up to half of patients despite significant hypoxemia. Children with severe disease may exhibit cyanosis, nasal flaring, and intercostal retractions. Rare extrapulmonary manifestations can involve the central nervous system, thyroid, gastrointestinal tract, lymph nodes, eyes, and bone marrow.
Laboratory findings are nonspecific. Elevated lactate dehydrogenase (LDH) levels are common but not diagnostic. Serum β-D-glucan levels are frequently elevated. Arterial blood gas analysis typically demonstrates hypoxemia, respiratory alkalosis, and an increased alveolar–arterial oxygen gradient. Disease severity is often classified according to the degree of alveolar–arterial gradient elevation.
Chest radiography classically demonstrates bilateral diffuse perihilar infiltrates, although early disease may show a normal chest x-ray. Chest CT scanning is more sensitive and commonly reveals diffuse bilateral ground-glass opacities. Patients receiving aerosolized pentamidine prophylaxis may show upper-lobe infiltrates and are at increased risk for pneumothorax.
Definitive diagnosis requires identification of the organism in respiratory specimens. Fiberoptic bronchoscopy with bronchoalveolar lavage remains the diagnostic standard. Induced sputum may be used but has variable sensitivity. Histopathologic stains such as methenamine silver, toluidine blue, Giemsa, and immunofluorescent stains are used to identify cysts and trophozoites. More invasive procedures such as transbronchial biopsy or open-lung biopsy are reserved for difficult cases.
The differential diagnosis includes other causes of diffuse pneumonia and respiratory failure, including tuberculosis, cytomegalovirus pneumonia, viral pneumonias, Legionella infection, fungal pneumonias, pulmonary embolism, ARDS, congestive heart failure, and pulmonary involvement by Kaposi sarcoma or lymphoma.
Trimethoprim-sulfamethoxazole (TMP-SMX) is the treatment of choice for PCP. The recommended dose is 15–20 mg/kg/day of the trimethoprim component, administered orally or intravenously in divided doses. Treatment duration is 21 days in HIV-infected patients and 14 days in non-HIV patients. Clinical improvement usually occurs within several days, although clinicians should wait at least 4–8 days before concluding treatment failure.
Adjunctive corticosteroids significantly improve survival in patients with moderate to severe disease, particularly in HIV-associated PCP. Steroids are indicated in patients with a PaO₂ below 70 mm Hg or an alveolar–arterial gradient greater than or equal to 35 mm Hg. Prednisone is typically administered in tapering doses over 21 days and should be started within 72 hours of initiating antimicrobial therapy.
Alternative therapies are used when TMP-SMX cannot be tolerated or when treatment failure occurs. Intravenous pentamidine is an effective alternative but may cause significant toxicities including hypotension, arrhythmias, pancreatitis, dysglycemia, renal dysfunction, electrolyte abnormalities, and neutropenia. Other options include clindamycin plus primaquine, atovaquone, or trimethoprim plus dapsone. Primaquine should be avoided in patients with glucose-6-phosphate dehydrogenase deficiency.
Patients require close monitoring for clinical response, oxygenation status, and medication-related adverse effects. Complications include progressive respiratory failure, pneumothorax, concurrent pulmonary infections, and death. Mortality rates are approximately 10–20% among HIV-infected patients but may reach 30–50% in non-HIV immunocompromised individuals, largely due to delayed diagnosis and treatment. Early recognition and prompt therapy remain essential for improving outcomes.
- Published on
Infectious disease and microbiology – Plague
Plague is a severe zoonotic infection caused by Yersinia pestis, a gram-negative aerobic coccobacillus belonging to the Enterobacteriaceae family. Historically, plague caused the devastating “Black Death” pandemics of the Middle Ages. Clinically, the disease may present as bubonic, septicemic, pneumonic, meningeal, or pharyngeal plague.
Plague remains endemic in several regions of the world, especially in parts of Africa, Asia, and the Americas. Between 1998 and 2003, more than 38,000 cases and nearly 3,000 deaths were reported globally. In the United States, most cases occur in the southwestern states, particularly New Mexico, Arizona, and Colorado.
Major risk factors include residence or travel in endemic areas, poor rodent control, exposure to rodents or rodent predators, occupational exposure among veterinarians and laboratory workers, close contact with infected animals, and inadequate flea control in domestic animals.
The disease is maintained in nature through an enzootic cycle involving rodents and fleas. Humans are accidental hosts and do not contribute significantly to maintaining transmission. Infection occurs through:
Clinical Forms
Bubonic plague
The most common presentation.
Symptoms
Septicemic plague
May occur primarily or as progression from bubonic disease.
Features
Pneumonic plague
The most dangerous and contagious form.
Symptoms
Meningeal plague
Rare complication due to CNS seeding during bacteremia.
Features
Diagnosis
Laboratory abnormalities may include:
Special culture media include:
Chest radiography in pneumonic plague may show:
Treatment
First-line therapy
Aminoglycosides
Alternative agents
Supportive Care
Management may also require:
Infection Control
Pneumonic plague
Requires:
Standard precautions are usually sufficient.
Healthcare and laboratory personnel should be informed immediately if plague is suspected because Y. pestis is considered a potential bioterrorism agent owing to its high virulence and aerosol transmissibility.
Prognosis and Complications
Untreated plague has mortality rates approaching 50%, while untreated pneumonic plague is almost universally fatal.
Complications include:
Plague is a severe zoonotic infection caused by Yersinia pestis, a gram-negative aerobic coccobacillus belonging to the Enterobacteriaceae family. Historically, plague caused the devastating “Black Death” pandemics of the Middle Ages. Clinically, the disease may present as bubonic, septicemic, pneumonic, meningeal, or pharyngeal plague.
Plague remains endemic in several regions of the world, especially in parts of Africa, Asia, and the Americas. Between 1998 and 2003, more than 38,000 cases and nearly 3,000 deaths were reported globally. In the United States, most cases occur in the southwestern states, particularly New Mexico, Arizona, and Colorado.
Major risk factors include residence or travel in endemic areas, poor rodent control, exposure to rodents or rodent predators, occupational exposure among veterinarians and laboratory workers, close contact with infected animals, and inadequate flea control in domestic animals.
The disease is maintained in nature through an enzootic cycle involving rodents and fleas. Humans are accidental hosts and do not contribute significantly to maintaining transmission. Infection occurs through:
- Bite of an infected flea
- Direct contact with infected animals or carcasses
- Inhalation of respiratory droplets from pneumonic plague patients or infected animals
Clinical Forms
Bubonic plague
The most common presentation.
Symptoms
- Sudden fever and chills
- Headache and weakness
- Painful swollen lymph nodes (“buboes”) appearing within 24 hours
- Large, tender, erythematous lymph nodes
- Usually inguinal or femoral nodes
- Buboes may ulcerate
- Flea-bite papules or pustules may be present
Septicemic plague
May occur primarily or as progression from bubonic disease.
Features
- Severe sepsis and toxic appearance
- Hypotension
- Gastrointestinal symptoms
- Disseminated intravascular coagulation
- Acral gangrene (“black death”)
- Buboes may be absent
Pneumonic plague
The most dangerous and contagious form.
Symptoms
- Rapidly progressive pneumonia
- Productive cough with bloody sputum
- Pleuritic chest pain
- Severe respiratory distress and hypoxia
Meningeal plague
Rare complication due to CNS seeding during bacteremia.
Features
- Fever
- Headache
- Neck stiffness
Diagnosis
Laboratory abnormalities may include:
- Leukocytosis
- Thrombocytopenia
- Elevated liver enzymes
- Elevated creatinine and BUN
- Disseminated intravascular coagulation in severe disease
- Bubo aspirates
- Sputum
- Throat swabs
- CSF
- Skin swabs
Special culture media include:
- MacConkey agar
- Chocolate agar
- Sheep blood agar
- Brain-heart infusion broth
Chest radiography in pneumonic plague may show:
- Lobar or patchy infiltrates
- Cavitation
- Pleural effusions
- ARDS-like diffuse opacities
Treatment
First-line therapy
Aminoglycosides
- Streptomycin 30 mg/kg/day IM in 2 divided doses
- Gentamicin 2.5 mg/kg IM every 12 hours
Alternative agents
- Doxycycline
- Tetracycline
- Chloramphenicol
- TMP-SMX
Supportive Care
Management may also require:
- Intravenous fluids
- Analgesics and antipyretics
- Intensive care support for septic shock or respiratory failure
Infection Control
Pneumonic plague
Requires:
- Respiratory droplet isolation
- Hospital admission
- Immediate antimicrobial treatment
Standard precautions are usually sufficient.
Healthcare and laboratory personnel should be informed immediately if plague is suspected because Y. pestis is considered a potential bioterrorism agent owing to its high virulence and aerosol transmissibility.
Prognosis and Complications
Untreated plague has mortality rates approaching 50%, while untreated pneumonic plague is almost universally fatal.
Complications include:
- Pneumonia
- Septic shock
- Multiorgan failure
- Respiratory failure
- Disseminated intravascular coagulation
- Secondary bacterial superinfection of buboes
- Published on
Infectious disease and microbiology – Pilonidal abscess
A pilonidal abscess is an infection of a pilonidal cyst, usually located in the postanal or sacrococcygeal region within the natal cleft. Pilonidal disease is now considered an acquired condition rather than congenital and ranges from asymptomatic pits to painful abscesses and chronic draining sinuses.
The disease is relatively common, with approximately 70,000 new cases annually in the United States. It occurs most often in young adults between 18 and 30 years of age and is significantly more common in males than females, with a male-to-female ratio of about 3:1. Higher rates are reported in Mediterranean populations, whereas the disease is relatively uncommon in East Asia, Oceania, and sub-Saharan Africa.
Several risk factors contribute to pilonidal disease, including male gender, obesity, excessive body hair, poor hygiene, and a deep natal cleft. Although prevention is difficult, maintaining good perianal hygiene and regular hair removal may reduce recurrence and progression.
The pathogenesis involves the formation of a hair follicle pit in the natal cleft, which enlarges and fills with keratin and debris. Hair penetration into the skin triggers a foreign body inflammatory reaction, leading to infection of the surrounding subcutaneous tissue. Chronic disease may result in sinus tract formation, with the direction of hair insertion influencing the tract pattern.
The exact microbial causes are variable, but infections are usually polymicrobial and involve organisms from the skin flora and bowel flora, including anaerobic bacteria.
Clinically, patients typically present with a painful, tender, warm, fluctuant swelling in the sacrococcygeal area during acute infection. Chronic disease may produce persistent or intermittent drainage from midline pits or sinus tracts, with symptoms waxing and waning over weeks.
Diagnosis is mainly clinical and based on physical examination. Characteristic findings include midline pits in the gluteal cleft, usually located approximately 5 cm above the anus. Acute abscesses, chronic sinus tracts, or minimal inflammation may be present. An anorectal examination is important to exclude other conditions.
The differential diagnosis includes both infectious and noninfectious disorders such as perianal abscess, hidradenitis suppurativa, necrotizing fasciitis, furunculosis, herpes simplex infection, syphilis, tuberculosis, anal fistulas, Crohn disease, coccygodynia, and radiation proctitis.
Management depends on the severity and chronicity of disease. Antibiotics alone have a limited role but may be useful in patients with associated cellulitis, systemic illness, or immunosuppression. When used, therapy should include anaerobic coverage. Meticulous local hygiene and hair removal are recommended as supportive measures.
For minimally symptomatic disease, nonsurgical therapies such as phenol or fibrin glue injection combined with hygiene and hair control may be attempted. However, the mainstay of treatment for most acute or chronic cases is surgical management. Limited excision with an off-midline incision and removal of the sinus pits is often sufficient and allows quicker recovery with acceptable recurrence rates. More extensive recurrent or complicated disease may require wide excision and reconstruction with flattening of the natal cleft, although this approach carries higher morbidity.
The overall prognosis is excellent, though recurrence is relatively common and may necessitate repeat or more extensive surgery. Rare complications include large abscesses leading to sepsis and shock, and in very long-standing untreated disease, the development of carcinoma arising from a chronic pilonidal sinus.
A pilonidal abscess is an infection of a pilonidal cyst, usually located in the postanal or sacrococcygeal region within the natal cleft. Pilonidal disease is now considered an acquired condition rather than congenital and ranges from asymptomatic pits to painful abscesses and chronic draining sinuses.
The disease is relatively common, with approximately 70,000 new cases annually in the United States. It occurs most often in young adults between 18 and 30 years of age and is significantly more common in males than females, with a male-to-female ratio of about 3:1. Higher rates are reported in Mediterranean populations, whereas the disease is relatively uncommon in East Asia, Oceania, and sub-Saharan Africa.
Several risk factors contribute to pilonidal disease, including male gender, obesity, excessive body hair, poor hygiene, and a deep natal cleft. Although prevention is difficult, maintaining good perianal hygiene and regular hair removal may reduce recurrence and progression.
The pathogenesis involves the formation of a hair follicle pit in the natal cleft, which enlarges and fills with keratin and debris. Hair penetration into the skin triggers a foreign body inflammatory reaction, leading to infection of the surrounding subcutaneous tissue. Chronic disease may result in sinus tract formation, with the direction of hair insertion influencing the tract pattern.
The exact microbial causes are variable, but infections are usually polymicrobial and involve organisms from the skin flora and bowel flora, including anaerobic bacteria.
Clinically, patients typically present with a painful, tender, warm, fluctuant swelling in the sacrococcygeal area during acute infection. Chronic disease may produce persistent or intermittent drainage from midline pits or sinus tracts, with symptoms waxing and waning over weeks.
Diagnosis is mainly clinical and based on physical examination. Characteristic findings include midline pits in the gluteal cleft, usually located approximately 5 cm above the anus. Acute abscesses, chronic sinus tracts, or minimal inflammation may be present. An anorectal examination is important to exclude other conditions.
The differential diagnosis includes both infectious and noninfectious disorders such as perianal abscess, hidradenitis suppurativa, necrotizing fasciitis, furunculosis, herpes simplex infection, syphilis, tuberculosis, anal fistulas, Crohn disease, coccygodynia, and radiation proctitis.
Management depends on the severity and chronicity of disease. Antibiotics alone have a limited role but may be useful in patients with associated cellulitis, systemic illness, or immunosuppression. When used, therapy should include anaerobic coverage. Meticulous local hygiene and hair removal are recommended as supportive measures.
For minimally symptomatic disease, nonsurgical therapies such as phenol or fibrin glue injection combined with hygiene and hair control may be attempted. However, the mainstay of treatment for most acute or chronic cases is surgical management. Limited excision with an off-midline incision and removal of the sinus pits is often sufficient and allows quicker recovery with acceptable recurrence rates. More extensive recurrent or complicated disease may require wide excision and reconstruction with flattening of the natal cleft, although this approach carries higher morbidity.
The overall prognosis is excellent, though recurrence is relatively common and may necessitate repeat or more extensive surgery. Rare complications include large abscesses leading to sepsis and shock, and in very long-standing untreated disease, the development of carcinoma arising from a chronic pilonidal sinus.
- Published on
Toxicology – Black Widow Spider (Latrodectus) Envenomation
Source
Black widow spiders are found throughout the United States, especially in warmer southern regions. Only female spiders bite humans. They are typically identified by markings on the abdomen—most commonly a red hourglass on the underside. These spiders tend to inhabit dark, undisturbed areas such as woodpiles, garages, and sheds.
Typical Presentation
Patients often present after a painful spider bite followed by progressive muscle pain and systemic symptoms. In children, symptoms may be severe and mimic other acute conditions such as abdominal emergencies.
Clinical Features
The bite initially causes localized pain, followed by redness and sweating at the site. Systemic symptoms may include muscle cramps and fasciculations, severe abdominal pain and rigidity, nausea, vomiting, weakness, headache, dizziness, chest pain, and elevated blood pressure. In some cases, unusual findings such as priapism may occur. Symptoms tend to be more severe in children and older adults.
Mechanism of Action
The venom contains alpha-latrotoxin, a potent neurotoxin that triggers massive release of neurotransmitters by opening presynaptic calcium channels. This results in widespread neuromuscular and autonomic stimulation.
Management
Treatment is primarily supportive, focusing on pain control and symptom management. Muscle relaxants may be used for cramping. Intravenous calcium has been used in some cases, though benefits are variable. Antivenom may be considered in severe cases, particularly in high-risk patients or those with significant systemic symptoms.
Key Points
Source
Black widow spiders are found throughout the United States, especially in warmer southern regions. Only female spiders bite humans. They are typically identified by markings on the abdomen—most commonly a red hourglass on the underside. These spiders tend to inhabit dark, undisturbed areas such as woodpiles, garages, and sheds.
Typical Presentation
Patients often present after a painful spider bite followed by progressive muscle pain and systemic symptoms. In children, symptoms may be severe and mimic other acute conditions such as abdominal emergencies.
Clinical Features
The bite initially causes localized pain, followed by redness and sweating at the site. Systemic symptoms may include muscle cramps and fasciculations, severe abdominal pain and rigidity, nausea, vomiting, weakness, headache, dizziness, chest pain, and elevated blood pressure. In some cases, unusual findings such as priapism may occur. Symptoms tend to be more severe in children and older adults.
Mechanism of Action
The venom contains alpha-latrotoxin, a potent neurotoxin that triggers massive release of neurotransmitters by opening presynaptic calcium channels. This results in widespread neuromuscular and autonomic stimulation.
Management
Treatment is primarily supportive, focusing on pain control and symptom management. Muscle relaxants may be used for cramping. Intravenous calcium has been used in some cases, though benefits are variable. Antivenom may be considered in severe cases, particularly in high-risk patients or those with significant systemic symptoms.
Key Points
- Symptoms may mimic conditions such as acute abdomen or cardiac ischemia.
- Severe complications can include hypertensive crises and respiratory compromise.
- Early recognition and supportive care are essential for good outcomes.
- Published on
Infectious disease and microbiology – Odontogenic infections
Odontogenic infections are infections originating from the teeth or their supporting structures, ranging from minor localized lesions (e.g., dental caries, pulpitis, periapical abscess) to severe deep tissue infections that can spread into the neck and surrounding fascial spaces. These infections are among the most common reasons for dental consultations worldwide, with conditions such as periapical abscesses, periodontal abscesses, and pericoronitis being frequent emergency presentations.
They arise from disruption of the normal oral biofilm, a complex bacterial ecosystem on tooth surfaces. Poor oral hygiene or systemic conditions can alter this balance, allowing pathogenic organisms to proliferate. The infections are typically polymicrobial, involving a mix of aerobic and anaerobic bacteria, most commonly Streptococcus species, anaerobes like Fusobacterium, Peptostreptococcus, and Actinomyces, and others. As disease progresses, there is often a shift from Gram-positive organisms in early gingivitis to Gram-negative anaerobes in advanced periodontitis.
Risk factors include poor oral hygiene, diabetes, immunodeficiency, malnutrition, smoking, pregnancy, advanced age, and reduced salivation. Hospitalized patients may have increased colonization with Gram-negative organisms, increasing the risk of more severe infections. Preventive strategies focus on maintaining oral hygiene, fluoride use, plaque control (e.g., chlorhexidine), and regular dental care.
Clinically, presentation varies by the specific condition. Pulpitis and periapical abscesses typically begin with tooth sensitivity to hot or cold, progressing to persistent, throbbing pain. Gingivitis presents with inflamed, bleeding gums and halitosis, while periodontitis leads to tooth mobility, pain, and pus formation due to destruction of supporting tissues. Severe infections may extend into deep fascial spaces, causing swelling, fever, trismus, dysphagia, and systemic illness.
Diagnosis is primarily clinical, supported by dental imaging such as X-rays, which can identify bone loss, abscesses, and structural damage. Advanced imaging (CT or MRI) is used when infection spreads beyond the oral cavity. Microbiological testing may help guide therapy, although infections are usually polymicrobial.
Management aims to eliminate the source of infection and reduce bacterial load. This typically involves mechanical debridement, drainage of abscesses, and removal of the affected tooth if necessary. Antibiotics are reserved for systemic involvement or severe local spread, with common choices including penicillin, clindamycin, amoxicillin-clavulanate, or combinations such as ampicillin with metronidazole. Regular dental follow-up and periodontal care are essential to prevent recurrence.
Complications can be serious if untreated, including osteomyelitis of the jaw, necrotizing fasciitis, sinusitis, orbital infections, and intracranial spread. A particularly dangerous condition is Ludwig’s angina, a rapidly progressing bilateral infection of the floor of the mouth that can compromise the airway. Other rare but severe complications include cavernous sinus thrombosis, brain abscess, and Lemierre’s syndrome, underscoring the importance of early recognition and treatment.
Odontogenic infections are infections originating from the teeth or their supporting structures, ranging from minor localized lesions (e.g., dental caries, pulpitis, periapical abscess) to severe deep tissue infections that can spread into the neck and surrounding fascial spaces. These infections are among the most common reasons for dental consultations worldwide, with conditions such as periapical abscesses, periodontal abscesses, and pericoronitis being frequent emergency presentations.
They arise from disruption of the normal oral biofilm, a complex bacterial ecosystem on tooth surfaces. Poor oral hygiene or systemic conditions can alter this balance, allowing pathogenic organisms to proliferate. The infections are typically polymicrobial, involving a mix of aerobic and anaerobic bacteria, most commonly Streptococcus species, anaerobes like Fusobacterium, Peptostreptococcus, and Actinomyces, and others. As disease progresses, there is often a shift from Gram-positive organisms in early gingivitis to Gram-negative anaerobes in advanced periodontitis.
Risk factors include poor oral hygiene, diabetes, immunodeficiency, malnutrition, smoking, pregnancy, advanced age, and reduced salivation. Hospitalized patients may have increased colonization with Gram-negative organisms, increasing the risk of more severe infections. Preventive strategies focus on maintaining oral hygiene, fluoride use, plaque control (e.g., chlorhexidine), and regular dental care.
Clinically, presentation varies by the specific condition. Pulpitis and periapical abscesses typically begin with tooth sensitivity to hot or cold, progressing to persistent, throbbing pain. Gingivitis presents with inflamed, bleeding gums and halitosis, while periodontitis leads to tooth mobility, pain, and pus formation due to destruction of supporting tissues. Severe infections may extend into deep fascial spaces, causing swelling, fever, trismus, dysphagia, and systemic illness.
Diagnosis is primarily clinical, supported by dental imaging such as X-rays, which can identify bone loss, abscesses, and structural damage. Advanced imaging (CT or MRI) is used when infection spreads beyond the oral cavity. Microbiological testing may help guide therapy, although infections are usually polymicrobial.
Management aims to eliminate the source of infection and reduce bacterial load. This typically involves mechanical debridement, drainage of abscesses, and removal of the affected tooth if necessary. Antibiotics are reserved for systemic involvement or severe local spread, with common choices including penicillin, clindamycin, amoxicillin-clavulanate, or combinations such as ampicillin with metronidazole. Regular dental follow-up and periodontal care are essential to prevent recurrence.
Complications can be serious if untreated, including osteomyelitis of the jaw, necrotizing fasciitis, sinusitis, orbital infections, and intracranial spread. A particularly dangerous condition is Ludwig’s angina, a rapidly progressing bilateral infection of the floor of the mouth that can compromise the airway. Other rare but severe complications include cavernous sinus thrombosis, brain abscess, and Lemierre’s syndrome, underscoring the importance of early recognition and treatment.
- Published on
Infectious disease and microbiology – Orchitis
Orchitis is an inflammatory condition of the testes, most commonly caused by infection. It often occurs alongside epididymitis (epididymo-orchitis), in which case both conditions share similar causative organisms. Unlike many other genitourinary infections, viral causes—especially mumps—play a significant role, particularly in isolated orchitis. Although relatively uncommon compared to other urinary tract infections in men, orchitis is frequently encountered in outpatient settings and is associated with epididymitis in up to 20–40% of cases.
The infection typically develops through either direct spread from the epididymis or hematogenous dissemination in primary testicular infection. Risk factors include urethral catheterization, sexually transmitted infections (STIs), and underlying epididymitis, while prevention focuses on safe sexual practices and vaccination against mumps.
The etiology varies by age and risk profile. In younger men (14–35 years), the most common bacterial causes are Neisseria gonorrhoeae and Chlamydia trachomatis, whereas in older individuals, enteric Gram-negative bacteria such as Escherichia coli, Klebsiella, and Proteus predominate. Viral orchitis is most frequently caused by mumps virus, particularly in post-pubertal males, where it occurs in 20–30% of infections. Less commonly, fungi and rare pathogens such as Brucella or Mycobacterium tuberculosis may be involved.
Clinically, patients present with testicular pain, swelling, and tenderness, often accompanied by fever, nausea, and systemic symptoms. Viral orchitis, especially mumps-related, typically has an abrupt onset, often following parotitis by several days. The condition usually resolves within 1–2 weeks, although residual tenderness may persist. On examination, testicular enlargement with a preserved cremasteric reflex is typical, helping differentiate it from testicular torsion—a critical diagnosis that must always be excluded.
Diagnosis is based on clinical findings supported by laboratory tests and imaging. Urinalysis, urine culture, and testing for STIs (including PCR for Chlamydia and Gonorrhea) are essential. In suspected viral cases, serologic testing or PCR can confirm the diagnosis. Color Doppler ultrasonography is particularly important to rule out testicular torsion, which is the most urgent differential diagnosis.
Management depends on the underlying cause. Bacterial orchitis is treated with appropriate antibiotics, often covering both gonorrhea and chlamydia empirically (e.g., ceftriaxone plus doxycycline). Enteric infections are treated with β-lactam/β-lactamase inhibitors, cephalosporins, or fluoroquinolones. In contrast, viral orchitis has no specific antiviral treatment, and management is supportive, including rest, scrotal elevation, and cold compresses. Surgical intervention may be required in cases of abscess formation or complications.
The prognosis is generally favorable, especially in viral cases like mumps orchitis, which rarely leads to infertility, although testicular atrophy and abnormalities in sperm parameters may occur. Potential complications include testicular infarction, abscess formation, pyocele, and, rarely, infertility, emphasizing the importance of timely diagnosis and appropriate management.
Orchitis is an inflammatory condition of the testes, most commonly caused by infection. It often occurs alongside epididymitis (epididymo-orchitis), in which case both conditions share similar causative organisms. Unlike many other genitourinary infections, viral causes—especially mumps—play a significant role, particularly in isolated orchitis. Although relatively uncommon compared to other urinary tract infections in men, orchitis is frequently encountered in outpatient settings and is associated with epididymitis in up to 20–40% of cases.
The infection typically develops through either direct spread from the epididymis or hematogenous dissemination in primary testicular infection. Risk factors include urethral catheterization, sexually transmitted infections (STIs), and underlying epididymitis, while prevention focuses on safe sexual practices and vaccination against mumps.
The etiology varies by age and risk profile. In younger men (14–35 years), the most common bacterial causes are Neisseria gonorrhoeae and Chlamydia trachomatis, whereas in older individuals, enteric Gram-negative bacteria such as Escherichia coli, Klebsiella, and Proteus predominate. Viral orchitis is most frequently caused by mumps virus, particularly in post-pubertal males, where it occurs in 20–30% of infections. Less commonly, fungi and rare pathogens such as Brucella or Mycobacterium tuberculosis may be involved.
Clinically, patients present with testicular pain, swelling, and tenderness, often accompanied by fever, nausea, and systemic symptoms. Viral orchitis, especially mumps-related, typically has an abrupt onset, often following parotitis by several days. The condition usually resolves within 1–2 weeks, although residual tenderness may persist. On examination, testicular enlargement with a preserved cremasteric reflex is typical, helping differentiate it from testicular torsion—a critical diagnosis that must always be excluded.
Diagnosis is based on clinical findings supported by laboratory tests and imaging. Urinalysis, urine culture, and testing for STIs (including PCR for Chlamydia and Gonorrhea) are essential. In suspected viral cases, serologic testing or PCR can confirm the diagnosis. Color Doppler ultrasonography is particularly important to rule out testicular torsion, which is the most urgent differential diagnosis.
Management depends on the underlying cause. Bacterial orchitis is treated with appropriate antibiotics, often covering both gonorrhea and chlamydia empirically (e.g., ceftriaxone plus doxycycline). Enteric infections are treated with β-lactam/β-lactamase inhibitors, cephalosporins, or fluoroquinolones. In contrast, viral orchitis has no specific antiviral treatment, and management is supportive, including rest, scrotal elevation, and cold compresses. Surgical intervention may be required in cases of abscess formation or complications.
The prognosis is generally favorable, especially in viral cases like mumps orchitis, which rarely leads to infertility, although testicular atrophy and abnormalities in sperm parameters may occur. Potential complications include testicular infarction, abscess formation, pyocele, and, rarely, infertility, emphasizing the importance of timely diagnosis and appropriate management.
- Published on
Infectious disease and microbiology – Parvovirus infection
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
Parvovirus B19 infection is a common viral illness with a wide spectrum of clinical manifestations, ranging from mild childhood disease to severe complications in high-risk groups. It is best known for causing erythema infectiosum (fifth disease), but it can also lead to transient aplastic crisis in patients with chronic hemolytic anemia, chronic anemia in immunocompromised individuals, and serious fetal complications such as hydrops fetalis and fetal death. Notably, it is responsible for the majority of aplastic crises in conditions like sickle cell disease.
The virus has a global distribution, with humans as the only reservoir. Seroprevalence increases with age, reaching 30–60% in adults, and infection commonly occurs in childhood outbreaks, particularly in late winter and early spring. Transmission occurs mainly via respiratory secretions, but can also occur through blood products, vertical (mother-to-fetus) transmission, and rarely nosocomial exposure.
After an incubation period of about one week, viremia develops and is followed by infection of erythroid precursor cells in the bone marrow, leading to temporary suppression of red blood cell production (pure red-cell aplasia). The characteristic rash and joint symptoms appear later and are immune-mediated. In immunocompromised patients, failure to mount an antibody response may result in persistent infection and chronic anemia.
Clinically, infection often begins with mild flu-like symptoms such as fever, malaise, headache, and myalgias. This is followed by the classic “slapped cheek” facial rash, which may spread as a lacy, reticular rash over the extremities. Joint symptoms, particularly symmetric polyarthropathy affecting the hands, wrists, and knees, are more common in adults, especially women. In patients with hemolytic disorders, the presentation may be dominated by severe anemia, often without rash.
Diagnosis in typical childhood cases is clinical, but laboratory confirmation can be achieved through detection of parvovirus-specific IgM antibodies or a rise in IgG titers. In immunocompromised patients, PCR detection of viral DNA is more reliable, as antibody responses may be absent. In aplastic crises, laboratory findings include severe anemia with low reticulocyte count and characteristic bone marrow findings (giant pronormoblasts).
Management is largely supportive, as infection in immunocompetent individuals is usually self-limited. Nonsteroidal anti-inflammatory drugs may help relieve joint symptoms. In severe cases, such as aplastic crisis or chronic anemia, treatment includes blood transfusions and intravenous immunoglobulin (IVIG). In immunocompromised patients, reducing immunosuppression when possible may aid recovery.
Special consideration is required during pregnancy, as fetal infection can result in severe anemia, hydrops fetalis, and fetal death, particularly in the first half of pregnancy. Monitoring with ultrasound and laboratory testing is essential, and intrauterine transfusion may be needed in severe cases.
The prognosis is excellent in healthy individuals, with most cases resolving without complications. However, complications can occur in vulnerable populations and include severe anemia, chronic infection, fetal loss, hepatitis, myocarditis, meningoencephalitis, and hemophagocytic syndrome. Overall, parvovirus B19 infection highlights the contrast between a typically mild childhood illness and its potentially serious impact in high-risk groups.
- Published on
Infectious disease and microbiology – Osteomyelitis
Osteomyelitis is an infection of bone, most commonly caused by bacteria and only rarely by fungi. It may present as acute disease, developing over days to weeks, or as chronic osteomyelitis, which evolves over months or years and is often associated with necrotic bone (sequestrum). The condition has an estimated incidence of 10–100 cases per 100,000 population and arises in a variety of clinical settings depending on host factors and route of infection.
Several risk factors predispose individuals to osteomyelitis, including diabetes mellitus (especially with foot ulcers), intravenous drug use, peripheral vascular disease, trauma, immunosuppression, and prior surgery or prosthetic implants. Certain organisms are associated with specific populations—for example, Salmonella in patients with sickle cell disease and Pseudomonas aeruginosa in intravenous drug users or puncture wounds through footwear. Preventive strategies emphasize good diabetic foot care and maintaining sterile surgical conditions, particularly for prosthetic procedures.
Infection reaches bone through three principal mechanisms: hematogenous spread, direct inoculation (trauma or surgery), or contiguous spread from nearby infected tissues. Once established, infection can involve the cortex, medullary cavity, and periosteum, leading to inflammation, abscess formation, and eventual bone necrosis. In children, infection commonly affects the metaphysis of long bones, whereas in adults, vertebral involvement is more typical.
The etiology is broad, with Staphylococcus aureus being the most common pathogen overall. Other causes include gram-negative organisms (e.g., Enterobacteriaceae), Pseudomonas, coagulase-negative staphylococci (especially in prosthetic infections), Mycobacterium tuberculosis, fungi such as Candida or endemic mycoses, and less commonly Brucella or organisms related to travel exposures.
Clinically, patients often present with localized bone pain, fever, swelling, and warmth over the affected area. Chronic cases may feature sinus tract formation with drainage. Recurrent or persistent cellulitis over a bony area should raise suspicion for underlying osteomyelitis. Diagnosis relies on a combination of laboratory testing and imaging, but the gold standard is bone biopsy for culture and histopathology, ideally obtained before antibiotic therapy. Blood cultures may identify the organism in up to 40% of acute cases, while inflammatory markers such as ESR are useful for monitoring disease activity.
Imaging plays a crucial role: plain X-rays may initially be normal, while MRI is highly sensitive, especially for spinal disease. CT scans can detect early cortical changes, and radionuclide scans are useful for early detection and identifying multifocal involvement. Advanced imaging such as PET may be helpful in chronic or unclear cases.
Management requires a combined medical and surgical approach. Prolonged antibiotic therapy (typically ≥6 weeks) is essential and should be tailored to the identified organism. For example, methicillin-susceptible S. aureus is treated with nafcillin or oxacillin, while MRSA requires vancomycin or alternative agents. Gram-negative infections are treated with fluoroquinolones or third-generation cephalosporins, and Pseudomonas infections require antipseudomonal agents. Importantly, surgical debridement of necrotic bone is often necessary, especially in chronic disease, and removal of infected prosthetic material may be required.
The prognosis is generally good for acute osteomyelitis with timely treatment but more guarded in chronic cases, where recurrence is common. Complications can be severe and include bone destruction, pathological fractures, epidural abscess with spinal cord compression, cranial neuropathies (in skull base involvement), amyloidosis, and even malignant transformation (Marjolin’s ulcer). Long-term follow-up is essential, as clinical and radiologic resolution may lag behind actual disease control.
Osteomyelitis is an infection of bone, most commonly caused by bacteria and only rarely by fungi. It may present as acute disease, developing over days to weeks, or as chronic osteomyelitis, which evolves over months or years and is often associated with necrotic bone (sequestrum). The condition has an estimated incidence of 10–100 cases per 100,000 population and arises in a variety of clinical settings depending on host factors and route of infection.
Several risk factors predispose individuals to osteomyelitis, including diabetes mellitus (especially with foot ulcers), intravenous drug use, peripheral vascular disease, trauma, immunosuppression, and prior surgery or prosthetic implants. Certain organisms are associated with specific populations—for example, Salmonella in patients with sickle cell disease and Pseudomonas aeruginosa in intravenous drug users or puncture wounds through footwear. Preventive strategies emphasize good diabetic foot care and maintaining sterile surgical conditions, particularly for prosthetic procedures.
Infection reaches bone through three principal mechanisms: hematogenous spread, direct inoculation (trauma or surgery), or contiguous spread from nearby infected tissues. Once established, infection can involve the cortex, medullary cavity, and periosteum, leading to inflammation, abscess formation, and eventual bone necrosis. In children, infection commonly affects the metaphysis of long bones, whereas in adults, vertebral involvement is more typical.
The etiology is broad, with Staphylococcus aureus being the most common pathogen overall. Other causes include gram-negative organisms (e.g., Enterobacteriaceae), Pseudomonas, coagulase-negative staphylococci (especially in prosthetic infections), Mycobacterium tuberculosis, fungi such as Candida or endemic mycoses, and less commonly Brucella or organisms related to travel exposures.
Clinically, patients often present with localized bone pain, fever, swelling, and warmth over the affected area. Chronic cases may feature sinus tract formation with drainage. Recurrent or persistent cellulitis over a bony area should raise suspicion for underlying osteomyelitis. Diagnosis relies on a combination of laboratory testing and imaging, but the gold standard is bone biopsy for culture and histopathology, ideally obtained before antibiotic therapy. Blood cultures may identify the organism in up to 40% of acute cases, while inflammatory markers such as ESR are useful for monitoring disease activity.
Imaging plays a crucial role: plain X-rays may initially be normal, while MRI is highly sensitive, especially for spinal disease. CT scans can detect early cortical changes, and radionuclide scans are useful for early detection and identifying multifocal involvement. Advanced imaging such as PET may be helpful in chronic or unclear cases.
Management requires a combined medical and surgical approach. Prolonged antibiotic therapy (typically ≥6 weeks) is essential and should be tailored to the identified organism. For example, methicillin-susceptible S. aureus is treated with nafcillin or oxacillin, while MRSA requires vancomycin or alternative agents. Gram-negative infections are treated with fluoroquinolones or third-generation cephalosporins, and Pseudomonas infections require antipseudomonal agents. Importantly, surgical debridement of necrotic bone is often necessary, especially in chronic disease, and removal of infected prosthetic material may be required.
The prognosis is generally good for acute osteomyelitis with timely treatment but more guarded in chronic cases, where recurrence is common. Complications can be severe and include bone destruction, pathological fractures, epidural abscess with spinal cord compression, cranial neuropathies (in skull base involvement), amyloidosis, and even malignant transformation (Marjolin’s ulcer). Long-term follow-up is essential, as clinical and radiologic resolution may lag behind actual disease control.
- Published on
Infectious disease and microbiology – Otitis media
Otitis media refers to inflammation of the middle ear, involving the mucosa and periosteum, and encompasses several clinical forms including acute otitis media (AOM), recurrent AOM, otitis media with effusion (OME), and chronic suppurative otitis media (CSOM). Acute otitis media is defined by the presence of middle-ear fluid along with signs of acute infection, whereas OME involves persistent fluid without active infection, and CSOM is characterized by chronic ear discharge through a perforated tympanic membrane, sometimes associated with cholesteatoma.
This condition is extremely common in children, with more than two-thirds experiencing at least one episode before age 3, and a peak incidence between 6–24 months. It is far less common in adults. Risk factors include eustachian tube dysfunction (often following viral upper respiratory infections), daycare attendance, passive smoking, congenital anomalies (e.g., cleft palate), immunodeficiency, and early age of first infection. Preventive strategies emphasize vaccination (pneumococcal, Haemophilus influenzae, influenza), breastfeeding, and appropriate early treatment.
The pathophysiology centers on eustachian tube dysfunction, leading to fluid accumulation in the middle ear, which serves as a medium for microbial growth. Viral infections often precede bacterial infection by causing mucosal swelling and obstruction.
The etiology varies by age and clinical form. In children, the most common pathogens are Streptococcus pneumoniae, Haemophilus influenzae (mostly nontypable), and Moraxella catarrhalis. Other organisms include group A streptococci and Staphylococcus aureus. In neonates, group B streptococci and gram-negative bacilli are important, while in adults, H. influenzae and S. pneumoniae predominate. Chronic suppurative otitis media often involves Pseudomonas aeruginosa, S. aureus, enteric gram-negative bacilli, and anaerobes.
Clinically, acute otitis media presents with ear pain, fever, and hearing loss, while infants may show nonspecific symptoms such as irritability or feeding difficulties. OME is often asymptomatic but may cause a feeling of fullness or mild hearing loss, whereas CSOM presents with chronic purulent discharge and hearing impairment.
Diagnosis relies on otoscopic examination, which typically shows a bulging, erythematous, and immobile tympanic membrane in acute disease, while OME shows a dull, hypomobile membrane without bulging. Tympanometry and hearing tests can help confirm middle-ear fluid and assess hearing loss. In complicated or chronic cases, CT imaging may be required to evaluate for cholesteatoma or mastoid involvement.
Treatment depends on the clinical scenario. Amoxicillin remains the first-line therapy for most cases of acute otitis media, with alternatives such as amoxicillin-clavulanate or cephalosporins used in resistant or recurrent cases. Macrolides or TMP-SMX may be used in penicillin-allergic patients. A watchful waiting approach may be appropriate in selected children over 6 months with mild symptoms. OME generally does not benefit from antibiotics, antihistamines, or decongestants, and is often managed with observation. CSOM requires topical antibiotics and often surgical intervention, especially if cholesteatoma is present.
Surgical options include tympanostomy tube placement for persistent effusion or recurrent infections, and adenoidectomy in selected cases. Pain control with analgesics is essential in all patients regardless of antibiotic use.
The prognosis for acute otitis media is excellent with appropriate treatment. However, complications can occur, particularly in untreated or severe cases, including mastoiditis, hearing loss, facial nerve paralysis, labyrinthitis, and intracranial infections such as meningitis or brain abscess. Careful follow-up is especially important in children with persistent effusion to prevent long-term hearing and developmental issues.
Otitis media refers to inflammation of the middle ear, involving the mucosa and periosteum, and encompasses several clinical forms including acute otitis media (AOM), recurrent AOM, otitis media with effusion (OME), and chronic suppurative otitis media (CSOM). Acute otitis media is defined by the presence of middle-ear fluid along with signs of acute infection, whereas OME involves persistent fluid without active infection, and CSOM is characterized by chronic ear discharge through a perforated tympanic membrane, sometimes associated with cholesteatoma.
This condition is extremely common in children, with more than two-thirds experiencing at least one episode before age 3, and a peak incidence between 6–24 months. It is far less common in adults. Risk factors include eustachian tube dysfunction (often following viral upper respiratory infections), daycare attendance, passive smoking, congenital anomalies (e.g., cleft palate), immunodeficiency, and early age of first infection. Preventive strategies emphasize vaccination (pneumococcal, Haemophilus influenzae, influenza), breastfeeding, and appropriate early treatment.
The pathophysiology centers on eustachian tube dysfunction, leading to fluid accumulation in the middle ear, which serves as a medium for microbial growth. Viral infections often precede bacterial infection by causing mucosal swelling and obstruction.
The etiology varies by age and clinical form. In children, the most common pathogens are Streptococcus pneumoniae, Haemophilus influenzae (mostly nontypable), and Moraxella catarrhalis. Other organisms include group A streptococci and Staphylococcus aureus. In neonates, group B streptococci and gram-negative bacilli are important, while in adults, H. influenzae and S. pneumoniae predominate. Chronic suppurative otitis media often involves Pseudomonas aeruginosa, S. aureus, enteric gram-negative bacilli, and anaerobes.
Clinically, acute otitis media presents with ear pain, fever, and hearing loss, while infants may show nonspecific symptoms such as irritability or feeding difficulties. OME is often asymptomatic but may cause a feeling of fullness or mild hearing loss, whereas CSOM presents with chronic purulent discharge and hearing impairment.
Diagnosis relies on otoscopic examination, which typically shows a bulging, erythematous, and immobile tympanic membrane in acute disease, while OME shows a dull, hypomobile membrane without bulging. Tympanometry and hearing tests can help confirm middle-ear fluid and assess hearing loss. In complicated or chronic cases, CT imaging may be required to evaluate for cholesteatoma or mastoid involvement.
Treatment depends on the clinical scenario. Amoxicillin remains the first-line therapy for most cases of acute otitis media, with alternatives such as amoxicillin-clavulanate or cephalosporins used in resistant or recurrent cases. Macrolides or TMP-SMX may be used in penicillin-allergic patients. A watchful waiting approach may be appropriate in selected children over 6 months with mild symptoms. OME generally does not benefit from antibiotics, antihistamines, or decongestants, and is often managed with observation. CSOM requires topical antibiotics and often surgical intervention, especially if cholesteatoma is present.
Surgical options include tympanostomy tube placement for persistent effusion or recurrent infections, and adenoidectomy in selected cases. Pain control with analgesics is essential in all patients regardless of antibiotic use.
The prognosis for acute otitis media is excellent with appropriate treatment. However, complications can occur, particularly in untreated or severe cases, including mastoiditis, hearing loss, facial nerve paralysis, labyrinthitis, and intracranial infections such as meningitis or brain abscess. Careful follow-up is especially important in children with persistent effusion to prevent long-term hearing and developmental issues.
